Intensity Therapeutics (INTS) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
The meeting was called to order at 10:30 A.M. Eastern Time and held virtually to improve stockholder access.
The agenda was made available online, with a Q&A session scheduled at the end.
Board and executive committee updates
Directors present included Dr. Emer Leahy, Dr. Mark Goldberg, Daniel Donovan, and Thomas Dubin.
Daniel Donovan and Thomas Dubin were candidates for re-election.
Joseph Talamo (CFO) and John Wesolowski (Controller) were introduced, along with legal counsel and the Inspector of Election.
Shareholder proposals
Proposals included the election of two directors, approval of the 2024 Employee Stock Purchase Plan, and ratification of EisnerAmper LLP as auditors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Intensity Therapeutics
- Net loss rose, cash reserves held at $9.5M, and resumed trials showed improved TNBC results.INTS
Q2 2026 - All proposals, including director elections and stock plan amendments, were approved by majority vote.INTSAGM 2026
- Net loss narrowed to $2.4M in Q1 2026; clinical progress and funding remain critical.INTSQ1 2026
- Shareholders will vote on director elections, equity plan changes, and auditor ratification at the 2026 virtual meeting.INTSProxy filing
- Virtual meeting to vote on director elections, auditor, and equity plan amendments.INTSProxy filing
- Promising clinical results and strong 2025 capital raise extend cash runway into Q2 2027.INTSQ4 2025
- Shelf registration enables up to $150M in offerings, supporting late-stage oncology trials.INTSRegistration Filing
- Registering 394,500 shares for resale; lead cancer drug advancing to Phase 3.INTSRegistration Filing
- Shareholders to vote on a reverse stock split and potential adjournment to maintain Nasdaq compliance.INTSProxy Filing